Medical/Pharmaceuticals
Clarity signs copper-67 Supply Agreement with Nusano
SYDNEY, Oct. 16, 2025 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce the signing of a Supp...
2025-10-16 21:04
4252
Volpara Earns ACR® Learning Network Vendor Partner Designation
LYNNWOOD, Wash., Oct. 16, 2025 /PRNewswire/ -- Volpara Health has qualified for the American College of Radiology® (ACR®) Learning Network Vendor Partner designation. Volpara Health partnered with one of the latest graduates of the ACR ImPower Program Mammography Positioning Improvement Collaborat...
2025-10-16 21:00
2135
Cell Publishes Breakthrough Research Results of IASO Bio's Anti-BCMA CAR-T Equecabtagene Autoleucel in Autoimmune Disease Multiple Sclerosis
SHANGHAI, NANJING, China and PLEASANTON, Calif., Oct. 16, 2025 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of innovative cell therapies, today announced that theCell published results fr...
2025-10-16 20:45
2449
Unixell Biotech reported a case study of UX-DA001, an iPSC-derived autologous cell therapy for Parkinson Diseases at MDS Congress 2025
SHANGHAI, Oct. 16, 2025 /PRNewswire/ -- Unixell Biotech, a clinical-stage bitotech company focused on developing innovative cell therapies for Parkinson'sdisease (PD) and other neurological disorders, announced positive 6-month follow-up data from the first patient in its phase 1 clinical trial ...
2025-10-16 20:35
2146
HARMONi-6 Phase III Study of Ivonescimab Accepted by The Lancet and Selected for ESMO 2025 LBA Presentation
HONG KONG, Oct. 16, 2025 /PRNewswire/ -- Akeso Inc. (9926.HK) today announced that the groundbreaking results from the registrational Phase III AK112-306/HARMONi-6 study of ivonescimab have been accepted for publication in The Lancet. The study evaluated ivonescimab, a first-in-class PD-1/VEGF b...
2025-10-16 12:15
2356
Jacobio Pharma Announces Strategic Partnership with Oceanpine Capital to Focus on Core Oncology Pipeline
BEIJING and SHANGHAI and BOSTON, Oct. 15, 2025 /PRNewswire/ -- Jacobio Pharma (1167.HK) today announced that its subsidiary, Beijing Jacobio Pharmaceuticals Co., Ltd. ("Beijing Jacobio"), has entered into a Capital Increase and Equity Transfer Agreement with Oceanpine Capital and an industry part...
2025-10-15 23:05
3264
SK bioscience Files for First-in-Human Trial of Universal Coronavirus Vaccine (Pan-sarbecovirus Vaccine) GBP511 Phase 1/2 study in Australia
* Candidate designed to protect against COVID-19 variants and broader Sarbecoviruses * Phase 1/2 study to enroll ~500 healthy adults, with topline results expected by 2028 * We aim to build a universal Sarbecovirus vaccine platform to proactively address future pandemics SEONGNAM, South Kor...
2025-10-15 20:00
4153
Nona Biosciences Appoints Dr. Di Hong as Chief Executive Officer to Drive Technology Innovation and Strategic Growth
CAMBRIDGE, Mass., Oct. 14, 2025 /PRNewswire/ -- Nona Biosciences ("Nona" or the "Company"), a global biotechnology company providing integrated solutions from "Idea to IND" (I to ITM), today announced the appointment of Dr. Di Hong as Chief Executive Officer (CEO). Dr. Hong will be based inShangh...
2025-10-15 08:00
1918
Mabwell Announces Latest Clinical Results of Novel B7-H3-Targeting ADC 7MW3711 to Be Presented at 2025 ESMO Congress
SHANGHAI, Oct. 14, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that clinical research results of its novel B7-H3-targeting ADC (R&D code: 7MW3711) for multiple advanced solid tumors, will be presented as a poster at the E...
2025-10-15 00:00
3797
Co-PSMA trial achieves primary endpoint
SYDNEY, Oct. 14, 2025 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce that the Co-PSMA (NCT...
2025-10-14 21:03
4084
Lunit AI Predicts Immunotherapy Outcome in Colorectal, Kidney, and Lung Cancer at ESMO 2025
AI-powered histopathology demonstrates predictive value for immunotherapy outcomes in pMMR mCRC, advanced ccRCC, and NSCLC with data featured in both oral and poster presentations SEOUL, South Korea, Oct. 14, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI for cancer diagnos...
2025-10-14 21:00
1781
India's No:1 Ranked Institute IIT Madras partners with Hyundai Motor India to launch 'Hyundai Hope for Cancer' to revolutionize Paediatric Cancer Care
CHENNAI, India, Oct. 14, 2025 /PRNewswire/ -- Indian Institute of Technology Madras (IIT Madras),India's No:1 Ranked Educational Institution, is partnering with Hyundai Motor India Foundation (HMIF), the CSR arm of Hyundai Motor India Limited (HMIL), to launch 'Hyundai Hope for Cancer' - a pionee...
2025-10-14 20:30
1835
Kyoto University Engineering Ph.D. Team Achieves Technology Transformation in Chengdu; LivingPhoenix's Biomimetic Collagen Rated "International Leading-Edge"
—— Globally Pioneering POGMENT Triple-Helix Biomimetic Collagen Debuts at Chinese Biomaterials Congress 2025 CHENGDU, China, Oct. 14, 2025 /PRNewswire/ -- The 2025 Chinese Biomaterials Congress recently convened in Shaoxing,Zhejiang, bringing together a prestigious gathering of leading minds in ...
2025-10-14 20:30
2133
Mabwell's CDH17-targeting ADC 7MW4911 Receives IND Clearance from NMPA
SHANGHAI, Oct. 14, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its self-developed CDH17-targeting ADC (R&D code: 7MW4911) received IND clearance from the National Medical Products Administration (NMPA) inChina to ini...
2025-10-14 20:00
2759
Clover Announces Positive Phase I Clinical Data for RSV-hMPV-PIV3 Combination Vaccines and for RSV Re-Vaccination in Older Adults
-- Results indicate potential best-in-class RSV+hMPV±PIV3 combination vaccines, with the potential ability to re-vaccinate individuals previously receiving approved RSV vaccines to restore and broaden protection-- -- Increases in neutralizing antibodies of approximately 6-8 fold for RSV, 6-9 fol...
2025-10-14 18:18
2256
Natural Field Drives Breakthroughs in Co-loading Liposome Technology, Accelerating Upgrading of Raw Materials for Cardiovascular and Gut Health
XIAN, China, Oct. 13, 2025 /PRNewswire/ -- Natural Field has achieved new continuous research breakthroughs in co-loading liposome technology, with remarkable progress particularly in the development of co-loading Coenzyme Q10 (CoQ10) liposome and co-loading curcumin liposome raw materials. This ...
2025-10-13 23:00
2411
Visionary Holdings (Nasdaq: GV) Secures Global License for Breakthrough Stem Cell Technology Aimed at Diabetes Remission and Potential Complete Cure in a USD 150 Billion Global Market
TORONTO, Oct. 13, 2025 /PRNewswire/ -- Visionary Holdings Inc. ("GV" or the "Company"), a technology-driven multinational enterprise listed on Nasdaq (Nasdaq: GV), today announced that its wholly owned subsidiary,Visionary Holdings (Asia) Limited, has entered into a Global Product and Technology ...
2025-10-13 21:40
2235
iRegene Therapeutics announced promising NouvNeu001 Phase I clinical data
CHENGDU, China, Oct. 13, 2025 /PRNewswire/ -- iRegene Therapeutics Co., Ltd. ("iRegene" or the "Company") is recognized as a biotechnology company pioneering chemically induced allogeneic cell therapy. iRegene's lead product, NouvNeu001, is the 1st iPSC therapy to receive IND approval from both t...
2025-10-13 21:00
1536
NEXTBIOMEDICAL Announces First Patient Enrolled in U.S. FDA Pivotal Trial of Nexsphere-F™ for Knee Osteoarthritis Pain
* RESORB Study Marks Major Step Toward U.S. Regulatory Approval and Global Commercialization SEOUL, South Korea, Oct. 13, 2025 /PRNewswire/ -- NEXTBIOMEDICAL CO., LTD. (KOSDAQ: 389650), an innovative medical device company based inSouth Korea, today announced the enrollment of the first patient...
2025-10-13 21:00
2522
Complete Genomics announces Gene by Gene as its newest sequencing service provider at ASHG
BOSTON, Oct. 13, 2025 /PRNewswire/ -- Complete Genomics
2025-10-13 21:00
2581
Week's Top Stories
Most Reposted
MetaOptics Sharpens Focus on Metalens Commercialisation; Withdraws Nasdaq Listing Application, and Defers U.S. Dual Listing Plan
[Picked up by 313 media titles]
2026-08-07 22:30Thailand Ready to Welcome 191 Countries to the 2026 Annual Meetings of the International Monetary Fund and the World Bank Group
[Picked up by 301 media titles]
2026-08-06 15:10
GCash Parent Mynt Cited as Sole Philippine Firm in World's Top Fintech Companies List
[Picked up by 296 media titles]
2026-08-12 16:02
MetaOptics Ltd achieves 79% of FY2025 full-year revenue in 1H 2026, on track to fulfil purchase orders of key metalens production equipment in 2H 2026
[Picked up by 293 media titles]
2026-08-11 19:03Two CityUHK scholars elected to the European Academy of Engineering in recognition of their internationally acclaimed research achievements
[Picked up by 292 media titles]
2026-08-10 19:12
Most Read
Thailand Ready to Welcome 191 Countries to the 2026 Annual Meetings of the International Monetary Fund and the World Bank Group
2026-08-06 15:10
19551
AMTD IDEA's Receipt of NYSE Letter Regarding ADS Trading Price's Below Compliance Standards
2026-08-08 04:01
13745
China Yuchai International Announces Unaudited 2026 First Half-Year Financial Results
2026-08-07 18:00
13492